48,466
edits
Difference between revisions of "P63"
Jump to navigation
Jump to search
→Positive - common use
| (5 intermediate revisions by the same user not shown) | |||
| Line 6: | Line 6: | ||
| Abbrev = | | Abbrev = | ||
| Synonyms = | | Synonyms = | ||
| Similar = p40 (more specific for squamous cell carcinoma) | | Similar = [[p40]] (more [[specificity|specific]] for squamous cell carcinoma) | ||
| Clones = | | Clones = | ||
| Use = breast pathology (invasion vs. in situ), prostate pathology (HGPIN vs. cancer), lung (adenocarcinoma vs. squamous) | | Use = breast pathology (invasion vs. in situ), prostate pathology (HGPIN vs. cancer), lung (adenocarcinoma vs. squamous) | ||
| Line 26: | Line 26: | ||
*Cytoplasmic staining suggestive of muscle differentiation - seen in [[rhabdomyosarcoma]].<ref name=pmid21623385>{{Cite journal | last1 = Martin | first1 = SE. | last2 = Temm | first2 = CJ. | last3 = Goheen | first3 = MP. | last4 = Ulbright | first4 = TM. | last5 = Hattab | first5 = EM. | title = Cytoplasmic p63 immunohistochemistry is a useful marker for muscle differentiation: an immunohistochemical and immunoelectron microscopic study. | journal = Mod Pathol | volume = 24 | issue = 10 | pages = 1320-6 | month = Oct | year = 2011 | doi = 10.1038/modpathol.2011.89 | PMID = 21623385 }}</ref> | *Cytoplasmic staining suggestive of muscle differentiation - seen in [[rhabdomyosarcoma]].<ref name=pmid21623385>{{Cite journal | last1 = Martin | first1 = SE. | last2 = Temm | first2 = CJ. | last3 = Goheen | first3 = MP. | last4 = Ulbright | first4 = TM. | last5 = Hattab | first5 = EM. | title = Cytoplasmic p63 immunohistochemistry is a useful marker for muscle differentiation: an immunohistochemical and immunoelectron microscopic study. | journal = Mod Pathol | volume = 24 | issue = 10 | pages = 1320-6 | month = Oct | year = 2011 | doi = 10.1038/modpathol.2011.89 | PMID = 21623385 }}</ref> | ||
== | ==Staining== | ||
===Positive=== | ===Positive - common use=== | ||
*Marker of [[squamous cell carcinoma]]. | *Marker of [[squamous cell carcinoma]]. | ||
*[[Urothelial carcinoma]].<ref name=pmid15976812>{{Cite journal | last1 = Lewis | first1 = JS. | last2 = Ritter | first2 = JH. | last3 = El-Mofty | first3 = S. | title = Alternative epithelial markers in sarcomatoid carcinomas of the head and neck, lung, and bladder-p63, MOC-31, and TTF-1. | journal = Mod Pathol | volume = 18 | issue = 11 | pages = 1471-81 | month = Nov | year = 2005 | doi = 10.1038/modpathol.3800451 | PMID = 15976812 | URL = http://www.nature.com/modpathol/journal/v18/n11/full/3800451a.html}}</ref> | *[[Urothelial carcinoma]].<ref name=pmid15976812>{{Cite journal | last1 = Lewis | first1 = JS. | last2 = Ritter | first2 = JH. | last3 = El-Mofty | first3 = S. | title = Alternative epithelial markers in sarcomatoid carcinomas of the head and neck, lung, and bladder-p63, MOC-31, and TTF-1. | journal = Mod Pathol | volume = 18 | issue = 11 | pages = 1471-81 | month = Nov | year = 2005 | doi = 10.1038/modpathol.3800451 | PMID = 15976812 | URL = http://www.nature.com/modpathol/journal/v18/n11/full/3800451a.html}}</ref> | ||
*[[Small cell carcinoma of the lung]] ~80% of cases.<ref name=pmid15551738>{{Cite journal | last1 = Au | first1 = NH. | last2 = Gown | first2 = AM. | last3 = Cheang | first3 = M. | last4 = Huntsman | first4 = D. | last5 = Yorida | first5 = E. | last6 = Elliott | first6 = WM. | last7 = Flint | first7 = J. | last8 = English | first8 = J. | last9 = Gilks | first9 = CB. | title = P63 expression in lung carcinoma: a tissue microarray study of 408 cases. | journal = Appl Immunohistochem Mol Morphol | volume = 12 | issue = 3 | pages = 240-7 | month = Sep | year = 2004 | doi = 10.1097/00129039-200409000-00010 | PMID = 15551738 }}</ref> | |||
===Invasive versus in situ=== | ===Invasive versus in situ=== | ||
| Line 35: | Line 36: | ||
*Prostate basal cell marker. | *Prostate basal cell marker. | ||
*Breast myoepithelial cell marker. | *Breast myoepithelial cell marker. | ||
===Negative=== | |||
[[Image:Poorly differentiated carcinoma -- p63 - intermed mag.jpg|thumb|right|200px|Negative p63 staining in a poorly differentiated [[carcinoma]].]] | |||
*[[Malignant mesothelioma]].<ref name=pmid18064689>{{Cite journal | last1 = Pu | first1 = RT. | last2 = Pang | first2 = Y. | last3 = Michael | first3 = CW. | title = Utility of WT-1, p63, MOC31, mesothelin, and cytokeratin (K903 and CK5/6) immunostains in differentiating adenocarcinoma, squamous cell carcinoma, and malignant mesothelioma in effusions. | journal = Diagn Cytopathol | volume = 36 | issue = 1 | pages = 20-5 | month = Jan | year = 2008 | doi = 10.1002/dc.20747 | PMID = 18064689 }}</ref> | |||
*[[Breast carcinoma]]. | |||
*[[Prostatic carcinoma]]. | |||
==Non-classic tumours== | ==Non-classic tumours== | ||